Venus Remedies stock jumps over 14% to 8-week high on FDA approval for anti-mircrobial resistance therapy

Shares of Venus Remedies rose 14.3% to ₹356.65 after the US FDA granted QIDP designation to its product VRP-034, targeting bloodstream infections. This designation offers regulatory benefits, highlighting the need for safer polymyxin therapies. The stock has rebounded 12% this month. 

Markets